Utilization of Colistin for Treatment of Multidrug-Resistant Pseudomonas aeruginosa

Simple item page
dc.contributor.authorSabuda, Deana M
dc.contributor.authorLaupland, Kevin
dc.contributor.authorPitout, Johann
dc.contributor.authorDalton, Bruce
dc.contributor.authorRabin, Harvey
dc.contributor.authorLouie, Thomas
dc.contributor.authorConly, John
dc.date.accessioned2018-09-27T12:11:06Z
dc.date.available2018-09-27T12:11:06Z
dc.date.issued2008-01-01
dc.date.updated2018-09-27T12:11:06Z
dc.description.abstractBACKGROUND: Colistin is uncommonly used in clinical practice; however, the emergence of multidrug-resistant organisms has rekindled interest in this potentially toxic therapeutic option. The present study describes the authors’ experience with colistin in the management of patients who were infected with metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa within the Calgary Health Region (Calgary, Alberta).METHOD: Adult patients who received colistimethate sodium (colistin) between January 2000 and December 2005 were identified via pharmacy records, and their charts were reviewed retrospectively. Patients with cystic fibrosis were excluded. Patient demographics, clinical course and relevant laboratory data were extracted.RESULTS: Twenty-eight courses of colistin were received by 22 patients. The majority of these treatments were directed at MBL-producing Pseudomonas. One-half of the patients received nebulized colistin. Intravenous (IV) colistin was administered to 12 patients for a mean ± SD of 14.7±13.8 days (range 3.7 to 46 days). The highest IV dose used was 125 mg every 6 h or 6 mg/kg/day. Eight of 12 patients (67%) treated with IV colistin responded either fully or partially. Two patients received IV colistin as outpatients. Adverse effects considered to be due to colistin included drug fever, nephrotoxicity and neurotoxicity. Five of nine patients (56%) who had complete data available for evaluation had at least a doubling of creatinine levels from baseline.CONCLUSION: Patients in the present study received both IV and nebulized colistin for multidrug-resistant P aeruginosa. The use of IV colistin was associated with a favourable response, but mild nephrotoxicity occurred in two-third of patients. It was concluded that colistin may be a useful drug when choices are limited.
dc.description.versionPeer Reviewed
dc.identifier.citationDeana M Sabuda, Kevin Laupland, Johann Pitout, et al., “Utilization of Colistin for Treatment of Multidrug-Resistant Pseudomonas aeruginosa,” Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 19, no. 6, pp. 413-418, 2008. doi:10.1155/2008/743197
dc.identifier.doihttps://doi.org/10.1155/2008/743197
dc.identifier.urihttp://hdl.handle.net/1880/108507
dc.identifier.urihttps://doi.org/10.11575/PRISM/44768
dc.language.rfc3066en
dc.rights.holderCopyright © 2008 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.titleUtilization of Colistin for Treatment of Multidrug-Resistant Pseudomonas aeruginosa
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
CJIDMM.2008.743197.pdf
Size:
519.82 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications